Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › mitoxantrone

mitoxantrone

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of mitoxantrone

40 trials tracked of mitoxantrone: 6 in phase 3 or 4 and 2 with published results. The most-cited published study has 111 citations.

40Trials tracked
6Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 6 Phase 2 31 Phase 1 2 Other / NA 1
  1. Phase 3 S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Completed · 111 cited
  2. Phase 3 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed · 101 cited
  3. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Completed
  4. Phase 3 XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer Completed
  5. Phase 3 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  6. Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Completed
Show 34 more trials
  1. Phase 2 A Study of Olaratumab (IMC-3G3) in Prostate Cancer Completed
  2. Phase 2 Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Completed
  3. Phase 2 Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy Completed
  4. Phase 2 A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer Completed
  5. Phase 2 High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML Completed
  6. Phase 2 Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML Completed
  7. Phase 2 Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer Completed
  8. Phase 2 Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell Completed
  9. Phase 2 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  10. Phase 2 Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma Completed
  11. Phase 2 Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma Completed
  12. Phase 2 S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed
  13. Phase 2 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  14. Phase 2 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed
  15. Phase 2 AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia Completed
  16. Phase 2 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  17. Phase 2 Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer Completed
  18. Phase 2 Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Completed
  19. Phase 2 Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia Completed
  20. Phase 2 FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years Completed
  21. Phase 2 Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Completed
  22. Phase 2 Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia Completed
  23. Phase 2 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Completed
  24. Phase 2 Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) Completed
  25. Phase 2 Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm Completed
  26. Phase 2 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Completed
  27. Phase 2 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma Completed
  28. Phase 2 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Completed
  29. Phase 2 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  30. Phase 2 Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed
  31. Phase 2 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Completed
  32. Phase 1 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed
  33. Phase 1 CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma Completed
  34. N/A Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) Completed

Showing the 40 most-cited and recently-updated of 40 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
Oncology Phase I
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Apr 12, 2026